AR115320A1 - Anticuerpo multivalente - Google Patents

Anticuerpo multivalente

Info

Publication number
AR115320A1
AR115320A1 ARP190100836A ARP190100836A AR115320A1 AR 115320 A1 AR115320 A1 AR 115320A1 AR P190100836 A ARP190100836 A AR P190100836A AR P190100836 A ARP190100836 A AR P190100836A AR 115320 A1 AR115320 A1 AR 115320A1
Authority
AR
Argentina
Prior art keywords
binding domain
antibody portion
base
additional binding
multivalent antibody
Prior art date
Application number
ARP190100836A
Other languages
English (en)
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of AR115320A1 publication Critical patent/AR115320A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente se refiere a un anticuerpo multivalente que comprende: una porción de anticuerpo de base que comprende dos dominios de unión; y al menos un dominio de unión adicional, en donde la porción de anticuerpo de base está conectada por un enlazador a al menos un dominio de unión adicional, en donde cada dominio de unión de la porción de anticuerpo de base y cada uno de los al menos uno de los dominios de unión adicionales tienen un común región variable, y en donde el enlazador comprende una secuencia de bisagra o una secuencia derivada de una secuencia de bisagra. La presente también se refiere a un anticuerpo multivalente que comprende: una porción de anticuerpo de base que comprende dos dominios de unión; y al menos un dominio de unión adicional, en donde al menos un dominio de unión adicional comprende una región CH1 y está conectado a la porción de anticuerpo de base por dicho enlazador, uniendo una región variable de la porción de anticuerpo de base y la región CH1, y en donde el anticuerpo multivalente se une a al menos tres epítopos diferentes.
ARP190100836A 2018-03-30 2019-03-29 Anticuerpo multivalente AR115320A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862650467P 2018-03-30 2018-03-30

Publications (1)

Publication Number Publication Date
AR115320A1 true AR115320A1 (es) 2020-12-23

Family

ID=66349617

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190100836A AR115320A1 (es) 2018-03-30 2019-03-29 Anticuerpo multivalente

Country Status (17)

Country Link
US (1) US11952424B2 (es)
EP (1) EP3774885A2 (es)
JP (1) JP2021519610A (es)
KR (1) KR20200139189A (es)
CN (1) CN111936514A (es)
AR (1) AR115320A1 (es)
AU (2) AU2019243665B2 (es)
BR (1) BR112020019795A2 (es)
CA (1) CA3094318A1 (es)
EA (1) EA202091871A1 (es)
IL (1) IL277672A (es)
MA (1) MA52212A (es)
MX (1) MX2020010267A (es)
PH (1) PH12020551504A1 (es)
SG (1) SG11202009036YA (es)
TW (1) TW202003569A (es)
WO (1) WO2019190327A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021519610A (ja) 2018-03-30 2021-08-12 メルス ナムローゼ フェンノートシャップ 多価抗体
SG11202105926QA (en) 2018-12-31 2021-07-29 Merus Nv Truncated multivalent multimers
CN113227132A (zh) 2018-12-31 2021-08-06 美勒斯公司 混合的结合域
TW202039578A (zh) 2019-03-29 2020-11-01 荷蘭商美勒斯公司 Cd3結合分子
MA55884A (fr) 2019-05-09 2022-03-16 Merus Nv Domaines variants pour la multimérisation de protéines et leur séparation
CA3165605A1 (en) 2019-12-24 2021-07-01 Merus N.V. Tgf-beta-rii binding proteins
EP4097131A1 (en) 2020-01-29 2022-12-07 Merus N.V. Means and method for modulating immune cell engaging effects
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
AR122132A1 (es) 2020-05-21 2022-08-17 Merus Nv Métodos y medios para producción de moléculas tipo ig
AU2023228391A1 (en) * 2022-03-03 2024-09-19 Pfizer Inc. Multispecific antibodies binding to il-4, il-13 and/or tslp and uses thereof
US20230383012A1 (en) * 2022-04-13 2023-11-30 Xencor, Inc. Antibodies that bind pd-l1, pd-l2, and/or cd28
WO2024144396A1 (en) 2022-12-27 2024-07-04 Merus N.V. Method for generating bispecific proteins
US20240262911A1 (en) * 2022-12-30 2024-08-08 Merus N.V. Promiscuous cd3 binding molecules
CN117946247B (zh) * 2023-02-23 2024-08-09 暨南大学 一种识别mage-a3抗原短肽的t细胞受体及其应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4118120A1 (de) * 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
DK2857516T3 (en) * 2000-04-11 2017-08-07 Genentech Inc Multivalent antibodies and uses thereof
US20040220388A1 (en) * 2000-06-30 2004-11-04 Nico Mertens Novel heterodimeric fusion proteins
JP2004523205A (ja) * 2000-07-25 2004-08-05 イムノメディクス， インコーポレイテッド 多価標的結合タンパク質
SI1523496T1 (sl) 2002-07-18 2011-11-30 Merus B V Rekombinantno proizvajanje zmesi protiteles
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
PT2147594E (pt) 2008-06-27 2014-02-17 Merus B V Mamíferos não humanos que produzem anticorpos
CN102245640B (zh) 2008-12-09 2014-12-31 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
AU2010249470B2 (en) 2009-05-20 2015-06-25 Novimmune S.A. Synthetic Polypeptide Libraries And Methods For Generating Naturally Diversified Polypeptide Variants
MX359551B (es) 2009-11-24 2018-10-02 Medimmune Ltd Agentes de union diana contra b7-h1.
EP2513312B1 (en) 2009-12-17 2015-03-18 NovImmune SA Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
EP2655415A4 (en) 2010-12-22 2016-03-09 Abbvie Inc THREE VARIABLE DOMAIN LINK PROTEINS AND USES THEREOF
CA2843158A1 (en) * 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
PT2785375T (pt) 2011-11-28 2020-10-29 Merck Patent Gmbh Anticorpos anti-pd-l1 e usos destes
EA035344B1 (ru) 2012-04-20 2020-05-29 Мерюс Н.В. Способ получения двух антител из одной клетки-хозяина
SG11201407190TA (en) 2012-05-15 2014-12-30 Bristol Myers Squibb Co Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
BR112014029883B1 (pt) 2012-05-31 2023-10-24 Sorrento Therapeutics Inc. Anticorpo recombinante anti-pd-l1 e uso de um anticorpo recombinante anti-pd-l1
US20150203591A1 (en) * 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
BR112015006824A2 (pt) 2012-09-27 2017-07-04 Merus B V anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
JP2016507523A (ja) 2013-02-05 2016-03-10 エンクマフ アーゲー ＣＤ３εおよびＢＣＭＡに対する二重特異的抗体
MX2015010843A (es) 2013-02-26 2016-04-04 Roche Glycart Ag Moleculas biespecificas de union al antigeno que activan celulas t.
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
EP4071177A1 (en) * 2013-12-30 2022-10-12 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
SI3110849T1 (sl) 2014-02-28 2021-01-29 Merus N.V. Protitelo, ki veže ERBB-2 in ERBB-3
SG11201607109QA (en) 2014-02-28 2016-09-29 Merus Nv Antibodies that bind egfr and erbb3
SG11201609917PA (en) 2014-05-29 2016-12-29 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
AU2015329966A1 (en) 2014-10-09 2017-04-27 Engmab Sàrl Bispecific antibodies against CD3epsilon and ROR1 for use in the treatment of ovarian cancer
EP3204415B1 (en) 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
WO2016105450A2 (en) * 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
CN114702586A (zh) 2015-03-13 2022-07-05 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
AU2016293942B2 (en) * 2015-07-10 2022-06-16 Merus N.V. Human CD3 binding antibody
MX2018001398A (es) 2015-08-03 2018-05-28 Engmab Sarl Anticuerpos monoclonales contra bcma.
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
PL3365373T3 (pl) * 2015-10-23 2021-08-23 Merus N.V. Molekuły wiążące, które hamują wzrost nowotworu
SG11201808289SA (en) 2016-03-25 2018-10-30 Biomunex Pharmaceuticals Binding molecules to cd38 and pd-l1
CN109415436A (zh) * 2016-04-27 2019-03-01 辉瑞公司 抗il-33抗体及其组合物、方法及用途
ES2952951T3 (es) 2016-04-28 2023-11-07 Biomunex Pharmaceuticals Anticuerpos biespecíficos dirigidos a EGFR y HER2
EA201990578A1 (ru) 2016-09-23 2019-10-31 Связывающие молекулы, которые модулируют биологическую активность, проявляемую клеткой
CN118359705A (zh) 2016-10-19 2024-07-19 英温拉公司 抗体构建体
EP4295918A3 (en) 2016-11-02 2024-03-20 Bristol-Myers Squibb Company Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
WO2018182420A1 (en) * 2017-03-31 2018-10-04 Merus N.V. Antibodies for the treatment of erbb-2/erbb-3 positive tumors
CN110650752A (zh) * 2017-03-31 2020-01-03 美勒斯公司 用于治疗具有NRG1融合基因的细胞的ErbB-2和ErbB3结合双特异性抗体
EP3649156A1 (en) * 2017-07-06 2020-05-13 Merus N.V. Antibodies that modulate a biological activity expressed by a cell
SG11202000014UA (en) * 2017-07-06 2020-01-30 Merus Nv Binding molecules that modulate a biological activity expressed by a cell
WO2019009727A1 (en) * 2017-07-06 2019-01-10 Merus N.V. ANTI-PD1 ANTI-TIM3 BISPECIFIC ANTIBODIES
BR112020002695A2 (pt) * 2017-08-09 2020-08-25 Merus N.V. anticorpos que se ligam à egfr e cmet
US20200384084A1 (en) * 2017-12-01 2020-12-10 Merus N.V. Use of bispecific antibody and il-15 for combination therapy
JP2021519610A (ja) 2018-03-30 2021-08-12 メルス ナムローゼ フェンノートシャップ 多価抗体
CN113227132A (zh) * 2018-12-31 2021-08-06 美勒斯公司 混合的结合域
MA55884A (fr) * 2019-05-09 2022-03-16 Merus Nv Domaines variants pour la multimérisation de protéines et leur séparation
BR112022010206A2 (pt) * 2019-11-26 2022-11-29 Novartis Ag Receptores de antígeno quiméricos e usos dos mesmos
EP4097131A1 (en) * 2020-01-29 2022-12-07 Merus N.V. Means and method for modulating immune cell engaging effects

Also Published As

Publication number Publication date
MA52212A (fr) 2021-02-17
US20190352401A1 (en) 2019-11-21
AU2023222983A1 (en) 2023-09-21
SG11202009036YA (en) 2020-10-29
BR112020019795A2 (pt) 2021-01-05
WO2019190327A2 (en) 2019-10-03
PH12020551504A1 (en) 2021-09-13
CA3094318A1 (en) 2019-10-03
IL277672A (en) 2020-11-30
US11952424B2 (en) 2024-04-09
EA202091871A1 (ru) 2021-06-22
CN111936514A (zh) 2020-11-13
TW202003569A (zh) 2020-01-16
JP2021519610A (ja) 2021-08-12
KR20200139189A (ko) 2020-12-11
AU2019243665A1 (en) 2020-10-08
WO2019190327A8 (en) 2021-06-17
EP3774885A2 (en) 2021-02-17
MX2020010267A (es) 2020-11-06
WO2019190327A3 (en) 2019-11-14
AU2019243665B2 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
AR115320A1 (es) Anticuerpo multivalente
CL2019001828A1 (es) Moléculas de unión a antígeno biespecíficas que comprenden el clon 20h4.9 anti-4-1bb.
UY31504A1 (es) Construcciones de union de antigenos
EA201692504A1 (ru) Триспецифичные связывающие молекулы и способы их применения
CO2019009076A2 (es) Anticuerpos biespecíficos de unión específica a pd1 y lag3
CL2020000662A1 (es) Contorsbodies 2+1 biespecíficos.
EA202190542A1 (ru) Сконструированные биспецифические белки
BR112018000475A2 (pt) construtos de anticorpo biespecíficos que se ligam a dll3 e a cd3
PE20211072A1 (es) Moleculas de union a antigeno capaces de unirse al cumulo de diferenciacion 3 (cd3) y al cumulo de diferenciacion 137 (cd137) pero no simultaneamente
AR069797A1 (es) Anticuerpos especificos bivalentes
CO6280542A2 (es) Anticuerpos bivalentes bioespecificos en donde en una cadena ligera y una cadena pesada, los dominios variables vl y vh estan reeplazados el uno por el otro
AR120515A2 (es) Conjugado de enzimas terapéuticas
BR112018075644A2 (pt) anticorpos anti-cd98 e conjugados de anticorpo e fármaco
BR112016015867A2 (pt) anticorpos de elevada afinidade e resistentes à agregação com base nas regiões variáveis vl e no derivado vhh
BR112018075651A2 (pt) anticorpos anti-cd98 e conjugados anticorpo fármaco
BR112021018451A2 (pt) Anticorpo biespecífico especificamente ligado a vegf e ang2
MX2022001220A (es) Neutralizacion de moleculas de union anti-influenza y usos de las mismas.
CO2019003759A2 (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos
MX2016006301A (es) Construcciones de unión a antígeno monovalente que se dirigen a egfr y/o her2, y sus usos.
EA202091161A1 (ru) Конъюгаты антител против cd22 с майтанзином, их комбинации и способы применения
CO2022013898A2 (es) Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
AR078046A1 (es) Proteinas de union a antigeno
BR112022013878A2 (pt) Anticorpos que ligam integrina avb8 e utilizações dos mesmos
UY37598A (es) Anticuerpos miméticos de fgf21 y usos de los mismos
BR112015021964A2 (pt) Anticorpo isolado ou um fragmento ligante de antígenos do mesmo que se liga especificamente a cxcl13, composição e seus usos